HC Wainwright resumed coverage on Abeona Therapeutics with a new price target
$ABEO
Biotechnology: Pharmaceutical Preparations
Health Care
HC Wainwright resumed coverage of Abeona Therapeutics with a rating of Buy and set a new price target of $8.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/2/2025 | $19.00 | Outperform | Oppenheimer |
| 3/5/2025 | $16.00 | Outperform | Oppenheimer |
| 7/3/2024 | $15.00 | Buy | H.C. Wainwright |
| 5/30/2024 | $21.00 | Buy | Stifel |
| 11/30/2021 | $5.00 → $1.00 | Outperform → Market Perform | SVB Leerink |
| 11/29/2021 | $5.00 → $4.00 | Buy | HC Wainwright & Co. |
| 7/19/2021 | $8.00 → $5.00 | Buy | HC Wainwright & Co. |
Oppenheimer resumed coverage of Abeona Therapeutics with a rating of Outperform and set a new price target of $19.00
Oppenheimer initiated coverage of Abeona Therapeutics with a rating of Outperform and set a new price target of $16.00
H.C. Wainwright initiated coverage of Abeona Therapeutics with a rating of Buy and set a new price target of $15.00
10-Q - ABEONA THERAPEUTICS INC. (0000318306) (Filer)
8-K - ABEONA THERAPEUTICS INC. (0000318306) (Filer)
DEFA14A - ABEONA THERAPEUTICS INC. (0000318306) (Filer)
CLEVELAND, June 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On May 31, 2026, the Compensation Committee of Abeona's Board of Directors granted restricted stock equity awards as a material inducement to employment to seven individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 13,800 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards will vest yearly on each anniversary of the grant date, such that the s
CLEVELAND, May 26, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced that members of its management team will participate in upcoming investor conferences in June 2026: 2026 Jefferies Global Healthcare Conference: Fireside chat at 3:10 PM ET on Thursday, June 4, 2026 and investor meetings.Goldman Sachs 47th Annual Global Healthcare Conference 2026: Investor meetings on Monday, June 8, 2026. A live webcast of the fireside chat can be accessed on the Investors section of the Abeona website under "Events" at https://investors.abeonatherapeutics.com/events, where a replay of the event will also be available for a limited time. About Abeona Therapeutics Abeona
- Three patients treated with ZEVASKYN® in Q1 2026 - - QTC network expands to six sites, with two new additions on the East Coast - - In-licensed radically novel engineered T-cell technology with game changing potential in the field of solid tumors; ophthalmology programs deprioritized - - $168.3M in cash, cash equivalents and short-term investments as of March 31, 2026 - - Webcast today at 8:30am ET - CLEVELAND, May 13, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today reported financial results for the first quarter of 2026, highlighting commercial momentum for ZEVASKYN. Steady increase in ZEVASKYN adoption with three patients completing treatment in the first
4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)
4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)
4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)
4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)
4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)
4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)
CLEVELAND, April 07, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced the appointment of Keith A. Goldan as a new independent member to its Board of Directors, effective as of April 1, 2026. Mr. Goldan will also serve as Chairman of Abeona's Audit Committee. Mr. Goldan brings more than two decades of financial leadership experience across publicly traded commercial-stage biotechnology and specialty pharmaceutical companies. His appointment to the Board of Directors reflects Abeona's continued focus on strengthening its leadership team to advance both strategic and financial objectives. "On behalf of the Board, we are delighted to welcome Keith to Abeona," sa
CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer (CBO). In this role, Mr. Tabrizi will lead the Company's corporate strategy and business development functions, as well as drive operating efficiency for the Company. "Mohamad brings a wealth of experience in strategic planning and business development," said Vish Seshadri, Chief Executive Officer of Abeona. "We look forward to leveraging his extensive network and proven expertise to optimize our operations and guide Abeona toward value-creating partnerships." Mr. Tabrizi transitions to Abeon
CLEVELAND, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced the appointment of James A. Gow, MD, MBA, MS, MHCM, as the Senior Vice President, Head of Clinical Development & Medical Affairs, effective immediately. "We are thrilled to welcome Dr. Gow to our executive team," said Vish Seshadri, Chief Executive Officer of Abeona. "James has a proven track record of leading novel gene therapy programs for inherited retinal diseases. His addition to our team will be invaluable as we advance our pipeline and deliver transformative treatments to patients."
SC 13G/A - ABEONA THERAPEUTICS INC. (0000318306) (Subject)
SC 13G/A - ABEONA THERAPEUTICS INC. (0000318306) (Subject)
SC 13G/A - ABEONA THERAPEUTICS INC. (0000318306) (Subject)
- Three patients treated with ZEVASKYN® in Q1 2026 - - QTC network expands to six sites, with two new additions on the East Coast - - In-licensed radically novel engineered T-cell technology with game changing potential in the field of solid tumors; ophthalmology programs deprioritized - - $168.3M in cash, cash equivalents and short-term investments as of March 31, 2026 - - Webcast today at 8:30am ET - CLEVELAND, May 13, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today reported financial results for the first quarter of 2026, highlighting commercial momentum for ZEVASKYN. Steady increase in ZEVASKYN adoption with three patients completing treatment in the first
CLEVELAND, May 04, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced it will host a conference call on Wednesday, May 13, 2026 at 8:30 a.m. ET to discuss its financial results for the first quarter of 2026 and corporate progress. The conference call will be available via phone and webcast. To access the call, dial 888-506-0062 (U.S. toll-free) or 973-528-0011 (international) and Entry Code: 305519 five minutes prior to the start of the call. A live, listen-only webcast and archived replay of the call can be accessed on the Investors & Media section of Abeona's website at https://investors.abeonatherapeutics.com/events. The archived webcast replay will be avai
- First ZEVASKYN® commercial patient treatment completed in December - - ZEVASKYN launch momentum building in first quarter 2026 – - $191.4M in cash, cash equivalents and short-term investments as of December 31, 2025 - CLEVELAND, March 17, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today reported financial results for the full year of 2025 and recent operational progress. "2026 is about building a steady cadence of biopsies and treatments," said Vish Seshadri, Chief Executive Officer of Abeona. "We are focused on ensuring every ZEVASKYN patient has a seamless experience throughout their treatment journey. Establishing these commercial foundations will position us